Approach to the therapy of hypereosinophilic syndromes.
With the introduction of new diagnostic methods and treatment modalities, it has become increasingly clear that hypereosinophilic syndromes (HES) are a heterogeneous group of disorders for which a single approach to treatment is insufficient. This article discusses current treatment modalities for myeloproliferative HES, idiopathic HES, and lymphocytic-variant HES.
Klion
Amy D
AD
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 4, Rm. 126, 4 Center Drive, Bethesda, MD 20892, USA. aklion@nih.gov
D016026:Bone Marrow Transplantation; D000529:Complementary Therapies; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy / Q000628:therapy*